Ipsen (IPSEY) & Its Rivals Critical Review

Ipsen (OTCMKTS: IPSEY) is one of 24 public companies in the “Diagnostic substances” industry, but how does it contrast to its rivals? We will compare Ipsen to similar businesses based on the strength of its analyst recommendations, earnings, valuation, dividends, profitability, institutional ownership and risk.

Profitability

How to Become a New Pot Stock Millionaire

This table compares Ipsen and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Ipsen N/A N/A N/A
Ipsen Competitors -884.88% -64.84% -17.51%

Volatility and Risk

Ipsen has a beta of -0.04, indicating that its share price is 104% less volatile than the S&P 500. Comparatively, Ipsen’s rivals have a beta of 1.44, indicating that their average share price is 44% more volatile than the S&P 500.

Institutional and Insider Ownership

0.0% of Ipsen shares are owned by institutional investors. Comparatively, 53.6% of shares of all “Diagnostic substances” companies are owned by institutional investors. 13.5% of shares of all “Diagnostic substances” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Dividends

Ipsen pays an annual dividend of $0.17 per share and has a dividend yield of 0.4%. Ipsen pays out 18.3% of its earnings in the form of a dividend. As a group, “Diagnostic substances” companies pay a dividend yield of 1.3% and pay out 41.9% of their earnings in the form of a dividend.

Earnings and Valuation

This table compares Ipsen and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Ipsen $2.27 billion $408.99 million 41.28
Ipsen Competitors $308.35 million $18.66 million -39.62

Ipsen has higher revenue and earnings than its rivals. Ipsen is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a summary of recent recommendations and price targets for Ipsen and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ipsen 0 0 1 0 3.00
Ipsen Competitors 101 367 567 19 2.48

As a group, “Diagnostic substances” companies have a potential upside of 15.07%. Given Ipsen’s rivals higher probable upside, analysts clearly believe Ipsen has less favorable growth aspects than its rivals.

Summary

Ipsen beats its rivals on 8 of the 14 factors compared.

About Ipsen

Ipsen S.A. operates as a pharmaceutical company worldwide. It operates in two segments, Primary Care and Specialty Care. The company offers drugs in oncology, endocrinology, neurology, gastroenterology, cognitive disorders, and rheumatology areas. Its products include Somatuline, which is an injectable treatment for acromegaly and neuroendocrine tumors; Decapeptyl, a synthetic hormone made of triptorelin and decapeptide analog of gonadotrophin releasing hormone, for the treatment of advanced metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, and female sterility; and Hexvix, a photosensitizing agent, for detection and resection of non invasive bladder cancer. The company also provides Cabometyx, a tablet formulation of cabozantinib for renal cell carcinoma; Cometriq for medullary thyroid cancer; Dysport for motor disorders and muscular spasticity; NutropinAq, a liquid formulation, for treating growth failure in children due to growth hormone deficiency in adults; and Increlex used for long-term treatment of growth failure in children and adolescents. In addition, it offers Smecta, a formulation for use in the treatment of chronic and acute diarrhea; Forlax, an osmotic laxative indicated for the symptomatic treatment of constipation in adults and children; and Tanaka for mild cognitive impairment related to age, pathophysiological deficiencies, vertigo, retinal deficits, acute or chronic hearing impairment, and tinnitus. Further, the company provides Adenuric for the treatment of gout; and Adrovance for treating post-menopausal osteoporosis. Additionally, it is developing chimeric somastatin and dopamine agonist molecule, VSN16R, OPS201, and OPS202 drugs, as well as botulinum toxin. Ipsen S.A. has a strategic agreement with Arix Bioscience plc to develop and commercialize various therapies. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy S.A.

Receive News & Ratings for Ipsen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ipsen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply